Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database

•Overall survival is the preferred main outcomes in randomized clinical trials design. However, its use is limited in case of rare events.•Time to progression and progression could be used instead of overall survival or as co-primary endpoint. The main advantages are the shorter observation time and...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Urologic oncology 2024-03, Vol.42 (3), p.69.e17-69.e25
Hauptverfasser:	Porreca, Annamaria, Di Nicola, Marta, Lucarelli, Giuseppe, Dorin, Vartolomei Mihai, Soria, Francesco, Terracciano, Daniela, Mistretta, Francesco Alessandro, Luzzago, Stefano, Buonerba, Carlo, Cantiello, Francesco, Mari, Andrea, Minervini, Andrea, Veccia, Alessandro, Antonelli, Alessandro, Musi, Gennaro, Hurle, Rodolfo, Busetto, Gian Maria, Del Giudice, Francesco, Ferretti, Simone, Perdonà, Sisto, Prete, Paola Del, Porreca, Angelo, Bove, Pierluigi, Crisan, Nicolae, Russo, Giorgio Ivan, Damiano, Rocco, Amparore, Daniele, Porpiglia, Francesco, Autorino, Riccardo, Piccinelli, Mattia, Brescia, Antonio, Tătaru, Sabin Octavian, Crocetto, Felice, Giudice, Arturo Lo, de Cobelli, Ottavio, Schips, Luigi, Ferro, Matteo, Marchioni, Michele
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - therapeutic use Administration, Intravesical Bacillus of Calmette-Guerin BCG Vaccine - therapeutic use High risk nonmuscle invasive bladder cancer Humans Neoplasm Invasiveness Neoplasm Recurrence, Local Non-Muscle Invasive Bladder Neoplasms Overall survival Progression-free survival Retrospective Studies Surrogate endpoint Treatment Failure Urinary Bladder Neoplasms - surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!